12.59 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||12.38 x 800|
|Ask||12.65 x 1000|
|Day's Range||12.50 - 13.47|
|52 Week Range||5.53 - 13.47|
|Beta (3Y Monthly)||0.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 8, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
Also, Wall Street analysts’ views on Toll Brothers, Bank of America, Cathay General Bancorp, Recro Pharma, and IBM
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
If you want to know who really controls Recro Pharma, Inc. (NASDAQ:REPH), then you'll have to look at the makeup of...
Recro Pharma (REPH) delivered earnings and revenue surprises of 63.89% and 29.90%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Record Results and Raising Guidance Announces Plan to Spin Acute Care Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., Aug. 08, 2019 -- Recro Pharma, Inc..
Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. The S&P 500 Index ETF (SPY) lost 2.6% in the first two months of the second quarter. Ten out of 11 industry groups in the S&P 500 Index lost value […]
Gerri Henwood has been the CEO of Recro Pharma, Inc. (NASDAQ:REPH) since 2008. This report will, first, examine the...
Gerri Henwood has been the CEO of Recro Pharma, Inc. (NASDAQ:REPH) since 2008. This analysis aims first to contrast...
Tech stocks are tumbling around like they're in a washing machine. Between the trade wars and varying economic numbers, chip stock have been all over the place. While the Nasdaq Biotech Index (INDEXNASDAQ:NBI) is up 7% year to date, it was a bumpy ride through the latter part of 2018.This year, the broad biotech sector has been buffeted along with other broad market indicators, considering that the weaker-than-expected U.S. economy and the continued trade war with China have slapped a question mark over that growth market.Also, U.S. healthcare seems to be frozen in place for now, so "silver bullet" medicines aren't getting the attention they deserve. And the administrations crackdown on funding and researchers at the National Institutes of Health are also challenging since most major drug discoveries start at NIH and are then pulled into R&D efforts at biotech and pharma companies.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 High-Quality Cheap Stocks to Buy With $10 But following are seven healthy biotech stocks to buy now. They get top scores in my Portfolio Grader for their fundamentals, earnings and momentum. These seven biotechs are both big and small, the one thing they have in common is growth now and in their future. Biotech Stocks to Buy: Repligen (RGEN)Repligen Corp (NASDAQ:RGEN) has had quite a good year, up 65% in the past 12 months, and 42% year to date. If a biotech or a Big Pharma are the bakeries that sell the finished goods, RGEN is the company that sells the ingredients and tools to the bakeries.It has three divisions: Chromotography (the separation of a mixture by passing it through a suspension), Filtration and OEM Products (usually proteins used for purification and cell growth products).These "ingredients" are certainly more complex than they are for a bakery, but they're just as fundamental to building drugs and manufacturing them with quality and consistency on a large scale.With a $3.6 billion market cap, RGEN is a good sized player with exposure across the industry, so it's a leveraged played on the fundamental growth in the biotech and pharmaceutical sector. And that's a solid investment moving forward. Vertex Pharma (VRTX)Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a big-cap pharmaceutical firm based out Boston, MA. It currently has three approved drugs to treat cystic fibrosis (CF) and has a number of drugs in the pipeline to treat other auto-immune diseases.Earlier this month it moved into the genetic therapy side of the business, expanding its relationship with CRISPR Therapeutics (CSPR) and buying gene therapy company Exonics Therapeutics.Exonics is involved in developing a gene therapy for Duchenne's muscular dystrophy (DMD). DMD is the most common form of the disease. It afflicts about 1 in 3,500 males and is usually recognized between the ages of 3 and 6 years of age. By age 10, most patients are wheelchair bound.Creating a gene therapy to resolve this rare disease would be massive. And given VRTX's history with CF, it has a very good shot. * 7 U.S. Stocks to Buy With Limited Trade War Exposure It's a relative outperformer in the big cap biotech space -- it sports a $43 billion market cap -- and is still a good value. Recro Pharma (REPH)Recro Pharma Inc (NASDAQ:REPH) is a small cap -- $206 million market cap -- that was launched in 2007. Its focus is on non-opioid, non-addictive pain and analgesics.It focuses its efforts on products for hospitals and ambulatory care facilities and works with generics to develop more effective delivery systems and more targeted markets.For example, its top-performing drug is meloxicam, an analgesic for post-operative pain that is administered intravenously. It also has an intranasal formulation of dexmedetomidine (Dex) for post-operative pain. Its third pipeline drug is fadolmidine and is similar to Dex but doesn't cross the blood-brain barrier.The stock is up 31% year to date and up 75% for the past 12 months. There's a good chance that its drugs could be fast-tracked considering the opioid crisis, which would get them to market even faster. Arrowhead Pharmaceuticals Corp (ARWR)Arrowhead Pharmaceuticals Corp (NASDAQ:ARWR) is a gene therapy biotech with a twist. Instead of using modified genes to eradicate a disease, it silences genes that are causing problems.Either way, this is a very hot sector and ARWR is one of the shining stars in the biotech heaven. It has a $2 billion market cap and has been around since 1989, which is means it has been through two or three waves of biotech booms and busts.The stock is on fire right now, up 108% year to date and 134% in the past year. Part of that is the news last October is signed a deal to license one of its drugs that targets hepatitis B to Janssen Pharmaceuticals. * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 It's pricey, but it has a lot of big new ahead of it. Veracyte (VCYT)Veracyte Inc (NASDAQ:VCYT) is also on the genetic side of the biotech sector. But it doesn't develop novel drugs, it produces genetic testing for various types of diseases.This is another new sector that is growing quickly because of the processing power now available to sequence genes and see how they tick.Right now, VCYT has genetic tests for thyroid cancer, lung cancer and a lung disease called idiopathic pulmonary fibrosis. The latter has been very hard to test for in the past, so VCYT testing is a big step forward.With a $1 billion market cap, VCYT is establishing a name for itself and already has products in the market, which is a very attractive business model compared to drug companies that will spend years and billions of dollars hoping a drug will get to the marketplace.Up and staggering 214% in the past year and 121% year to date, VCYT is just getting started. And could be a serious takeover candidate. Affimed (AFMD)Affimed NV (NASDAQ:AFMD) is a Germany-based biotech that is focused on immunotherapy work. This line of work is built on the premise that you can find a way for each individual to help combat disease using their own immune system.This is highly complex and is in earlier stages than gene therapy but it has enormous potential, especially in treating various cancers.AFMD has a proprietary ROCK(R) platform for recognizing and attacking certain types of cancers. It cancelled phase 1 studies in October of AFM11 to focus on its innate cell engager AFM24.Immuno-oncology is more than just working with a patient's immune system. It also means individualized treatment solutions for each patient. That would be a massive shift in the way disease care is viewed. And it's getting very close. * 7 Dividend Stocks That Are Worth Your Money Also, being a German company, it would have access to the European markets as well as the U.S. markets due to its partnership with Genentech. But it's a small cap with some work to do, so be patient. Incyte Corp (INCY)Incyte Corp (NASDAQ:INCY) is a Delaware-based biotech that is another good-sized player with a market cap of $16 billion.It has one drug that has been in the marketplace for years now. JAKAFI is a treatment for a rare form of bone marrow cancer and it also has a use as a treatment for host-done issues with bone marrow transplants.When you have drugs for rare diseases you have less competition and you can also charge more since there is few to no competitors but the market is also very small. But this does help start generating revenue for a company that can then use that cash to develop more drugs without burning through cash waiting for a big breakthrough.INCY has cooperative agreements with Merck (MRK) and Bristol Myers Squibb (BMY) using a new drug to work with their immuno-oncology drugs that are already on the market. This could be a big opportunity since these two Big Pharma firms could help get this combination through regulatory hurdles.The stock is up 21% year to date but only 4% in the past year. Its partnerships with leading Big Pharma firms is a strategic play on broader industry exposure.Louis Navellier is a renowned growth investor. He is the editor of five investing newsletters: Blue Chip Growth, Emerging Growth, Ultimate Growth, Family Trust and Platinum Growth. His most popular service, Blue Chip Growth, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors Compare Brokers The post 7 Top-Rated Biotech Stocks to Invest In Today appeared first on InvestorPlace.
If you want to compound wealth in the stock market, you can do so by buying an index fund. But one can do better than...
We hear a lot about the major averages on a day-to-day basis. But what we don't hear about nearly as much are the low-priced stocks and the small-cap stocks to buy that are primed to do well in this kind of market.Assuming all works out in the trade wars, we have going now and we don't pick any more trade fights with major trade partners, the U.S. economy should do well this year.And small cap companies can leverage growth far better than big ones, so this will be an ideal time for small caps in general, especially now that the Federal Reserve has announced it's will to err on the side of growth and lower interest rates if necessary, to keep growth moving.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best Stocks for 2019 -- So Far What's more, these stocks are all in strong growth sectors that won't be harmed by the current trade wars. That also makes my Portfolio Grader's seven A-rated stocks to buy under $10 attractive buyout targets for larger companies that can borrow at very low rates for acquisitions. Recro Pharma (REPH)Recro Pharma (NASDAQ:REPH) is a biotech that is in phase 3 trials for a non-opioid drug for acute post-operative pain. That has garnered it a great deal of attention over the past couple of years.With a market cap of $250 million, it has the wherewithal to mount a good effort in getting this drug over the finish line. Once it finishes trials successfully, it then can either shop the big drug firms for a licensing agreement, go on its own or get acquired by a pharma firm looking to diversify its portfolio.But the fact that taking a drug through drug trials can cost around $2 billion today means that small firms with good ideas can find it hard to keep generating revenue until they make it through trials.REPH is generating revenue now as it works on getting its Meloxicam through phase 3 trials. It has two other drugs in the pipeline as well. And its Q1 earnings report was very encouraging.While earnings were negative, they beat estimates by 87% and revenues were positive. It looks like it will break even by the end of this year and once Meloxicam gets through its hurdles, it may well be off to the races. Paysign (PAYS)Paysign (NASDAQ:PAYS) is a leader in the prepaid card business. Whether it's a phone card, rewards card or payment card, it does it all.This has become a very hot sector recently for temporary and unbanked workers. Instead of dealing with all the issues around delivery a check to workers, they can be given a prepaid card with their earnings on it to use as they please.Many of the big pharmaceutical firms are also using prepaid cards to give to patients as co-pay help for name brand pharmaceuticals. Local and state governments are also choosing prepaid cards rather then issuing checks to citizens as well as vendors. * 7 Stocks to Buy That Don't Care About Tariffs In the past year, PAYS is up a whopping 344%, 184% of that is year to date performance. Given that massive run, the stock is already at the $10 mark, but it's close enough and its potential is big enough that it makes this list. India Globalization Capital Inc (IGC)India Globalization Capital Inc (NYSE:IGC) is an odd combination of businesses. On the one hand, and as its name implies, it has a heavy-duty construction business and an industrial commodities trading business that has been in operation in India for 35 years.And then recently, it has added a cannabinoid therapeutics business, looking for and delivering alternative therapies for Alzheimer's and Parkinson's diseases.It was delisted from the NYSE after the price fell below $1 last year. But it won a relisting in February and the stock rose 234% on its first day of relisting. For the year, the stock is up 64% and year-to-date it's still up 232%. Its cannabis business is likely attracting much of the attention since many companies in the sector are getting purchased at massive premiums. At current prices, this isn't the stock to bet your retirement on, but it's certainly worth some fun money. Pedvco (PED)Pedvco Corp (NYSE:PED) stands for Pacific Energy Development Corp. It's an independent exploration and production company (E&P) that looks for oil and natural gas in Colorado's Niobrara Shale and Eagle Ford Shale in Texas.This is a good time to be an E&P, as the U.S. begins to ramp up energy exports. Not only does the solid economy bode well for demand growth, but overseas markets are paying premium prices for energy supplies, especially natural gas.There are new natural gas export facilities opening in the next few years, which will make natural gas an even more valuable commodity. * 7 Best ETFs for a Well-Balanced Portfolio What's more, the consolidation underway in the E&P sector bodes well for PED prospects of getting bought out by a bigger E&P or a diversified player. Up 560% in the past year, the stock is still trading a P/E below of 0.5. Yowza. Flexible Solutions International (FSI)Flexible Solutions International Inc (NYSE:FSI) is a Canada-based firm that has some interesting products built to conserve water and energy. One of its key products is a liquid blanket that you put over open water sources like swimming pools or fracking ponds to inhibit evaporation and maintain a stable temperature.Its other big product line is used by energy, utility, chemical and mining firms to prevent scaling and corrosion in water piping.This is an increasingly important aspect of the unconventional drilling methods that are used to get oil and natural gas out of the U.S. and Canadian shale regions. As those operations expand, so does FSI's potential business.The stock is up 94% year to date and still delivers an impressive 4.6% dividend. And its Q1 earnings report shows that growth is continuing. Sales were up 108% compared to the same quarter last year, and that includes a payment of $250,000 in U.S. tariffs. Net income was up almost 15%. And the P/E is still around 13. Sachem Capital (SACH)Sachem Capital Corp (NYSE:SACH) is a regional mortgage originator and lender of short-term loans (1-3 years) secured by first mortgage liens in the Connecticut, Massachusetts, New York and Rhode Island area.SACH primarily lends to acquire or renovate residential properties, acquire or construct properties or simply buy and hold existing properties. Given the short-term nature of the loans, much of the lending is to developers who build out properties and then sell them within the window.Given the low interest rate environment we're in currently, business is going to get even better since this is a great time to take on debt and lending is easier than it has been. * 10 Stocks to Buy That Could Be Takeover Targets This is borne out SACH's recent Q1 earnings in mid-May. Revenue was up 23% and net income was up 4%. The stock is up 33% for the year and it's still delivering a whopping 9.2% dividend. DHT Holdings (DHT)DHT Holdings Inc (NYSE:DHT) is an independent crude oil tanker company, with more than two dozen ships in its fleet.Most of these tankers are leased out to integrated oil companies to ship products around the world. Given the general growth in the global economy, and the expansion of export efforts in the U.S. market, tankers as a sector are doing well now. Usually, the summer is a slow time for them since much of the summer oil was delivered earlier for refining and in tanks for the summer demand season.The thing is, lower oil prices always mean that import-dependent countries stock up on oil and that keeps tanker fleets busy as well. DHT is up 47% YTD and that momentum should only increase if the trade wars dissipate. Plus, DHT also sports a 2.9% dividend, which comes in handy.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% * 7 Stocks to Buy That Don't Care About Tariffs * 5 Healthcare Stocks to Pick Up From the Wreckage Compare Brokers The post 7 A-Rated Stocks to Buy Under $10 appeared first on InvestorPlace.
Live and archived webcasts of the presentations will be available on the Presentations page of the company’s website at http://recropharma.com. Recro Pharma is a specialty pharma company that operates through two business divisions, a revenue-generating contract development and manufacturing, or CDMO, division, located in Gainesville, GA and an Acute Care division primarily focused on products for the hospital and other acute care settings.
Recro Pharma (REPH) delivered earnings and revenue surprises of 87.34% and 22.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 10 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
MALVERN, Philadelphia, May 10, 2019 -- Recro Pharma, Inc. (NASDAQ:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing.